1-3 of 3
Sarah Warren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Isabelle Girault, Julien Adam, Shensi Shen, Séverine Roy, Caroline Brard, Sara Faouzi, Emilie Routier, Jéremy Lupu, Sarah Warren, Kristina Sorg, SuFey Ong, Pascale Morel, Jean-Yves Scoazec, Stéphan Vagner, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 518–525.
https://doi.org/10.1158/1078-0432.CCR-21-1229
Published: 01 February 2022
View article titled, A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Open the PDF for A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6156–6163.
https://doi.org/10.1158/1078-0432.CCR-21-2103
Published: 15 November 2021
View article titled, Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Open the PDF for Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Saranya Chumsri, Daniel J. Serie, Zhuo Li, Katherine L. Pogue-Geile, Aixa E. Soyano-Muller, Afshin Mashadi-Hossein, Sarah Warren, Yanyan Lou, Gerardo Colon-Otero, Keith L. Knutson, Edith A. Perez, Alvaro Moreno-Aspitia, E. Aubrey Thompson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4422–4430.
https://doi.org/10.1158/1078-0432.CCR-18-2206
Published: 15 July 2019
View article titled, Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Open the PDF for Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials in another window
Includes: Supplementary data